Introduction: Hyperthyroidism in children and adolescents, although uncommon, has significant effects on growth, neurodevelopment, and quality of life. Local data in Malaysia are limited, and regional variations may influence disease presentation and outcomes. This study aimed to determine the incidence, clinical characteristics, and treatment outcomes of paediatric hyperthyroidism at a tertiary centre. Methodology: A retrospective cohort study was conducted at the Paediatric Endocrine Clinic, Universiti Malaya Medical Centre, from 2014 to 2024. Patients aged below 18 years with confirmed hyperthyroidism were included. Demographic, clinical, biochemical, and treatment data were analyzed. Descriptive statistics were used, and associations were tested using chisquare and Fisher’s exact tests, with p <0.05 considered significant. Results: Forty-three patients were included, representing 9.7% of paediatric thyroid disorders. The cohort was predominantly female (74.4%) and majority Malay, with a median age of 11.7 years. Most patients presented with typical features, including palpitations (72.5%), goiter (62.5%), weight loss (45.0%), and heat intolerance (40.0%). However, atypical presentations such as learning difficulties and psychological disturbances were also observed and, in some cases, constituted the chief complaints. Notably, 82.5% of patients presented with severe thyrotoxicosis. Grave’s disease was the predominant etiology. All patients received antithyroid drugs, mainly carbimazole, with 80.0% achieving disease control and a median time to euthyroid state of 2 months. The duration of antithyroid drug therapy prior to cessation was shorter than international recommendations, indicating a significant reduction in time to treatment completion. Relapse occurred in 25.0% and was significantly associated with poor disease control (p = 0.014), while no significant associations were found with demographic or biochemical factors. Definitive therapy was required in 35.0%, with older age, growth stunting, and prior relapse identified as significant predictors (p <0.05). Conclusion Paediatric hyperthyroidism in this Malaysian cohort is predominantly due to Graves’ disease and frequently presents with both classical and atypical manifestations, which may delay diagnosis. Despite a high proportion of severe thyrotoxicosis at presentation, antithyroid drug therapy was effective, with a shorter duration to treatment cessation compared to international standards. Poor disease control emerged as the strongest predictor of relapse, while older age, growth stunting, and prior relapse predicted progression to definitive therapy. Early recognition and individualized management are essential to optimize outcomes. Larger multicentre studies are needed to inform national clinical practice guidelines.
Adolescent ; Child ; Incidence ; Hyperthyroidism

Introduction: Childhood obesity is associated with significant metabolic morbidity, particularly insulin resistance (IR) and metabolic syndrome. Acanthosis nigricans (AN) is frequently observed in children with obesity and may represent a practical clinical marker of IR. This study evaluated the association between AN, IR, and metabolic complications in paediatric obesity. Methodology: A retrospective review was performed of 148 children (88 males, 60 females; median age 12 years) attending the Paediatric Obesity Clinic at Universiti Malaya Medical Centre. Data included anthropometry, AN grading, family history, HOMA-IR, and metabolic screening. Outcomes assessed were dyslipidemia, metabolic-associated fatty liver disease (MAFLD), hypertension, obstructive sleep apnea syndrome (OSAS), and glucose dysregulation. Comparisons were made between children with and without AN at baseline and over follow-up (median 2.4 years). Results: AN was present in 81.8% of patients, and 82.4% had central obesity. Increasing AN grade was significantly associated with higher BMI SDS and American Academy of Paediatrics obesity class (p <0.05). AN was more prevalent among Malay and Indian children and was associated with a family history of obesity (p <0.05). Baseline metabolic abnormalities were common, including dyslipidemia (high triglycerides 31.8%, low HDL 30.4%, high LDL 29.7%), MAFLD (23.6%), OSAS (31.1%), and glucose dysregulation (27.7%), with no significant difference between groups. During follow-up, children with AN and more severe obesity developed significantly more metabolic complications, particularly MAFLD and OSAS, with increased requirement for non-invasive ventilation (p <0.05). Higher HOMA-IR was associated with glucose dysregulation but was not independently associated with AN. Conclusion AN is strongly associated with greater adiposity and predicts the progression of metabolic complications in children with obesity. Routine assessment of AN may help identify high-risk patients who would benefit from early, intensive intervention to reduce long-term cardiometabolic morbidity
Child ; Acanthosis Nigricans ; Biomarkers ; Obesity

BACKGROUND

The recent COVID-19 pandemic has led to a rise in the incidence of obesity both in children and adults. Studies on the effect of the pandemic on Type 2 diabetes mellitus (T2DM) trends in children are limited. In this study, we aim to evaluate the frequency, clinical characteristics and demographics of newly-diagnosed paediatric T2DM cases 4 years before and after the pandemic.

METHODOLOGY

The frequency and clinical data of patients aged ≤18 years with newly-diagnosed T2DM in 4 tertiary centers in urban Malaysia from 18 March 2016 till 17 March 2020 (pre-pandemic) and 18 March 2020 till 17 March 2024 (postpandemic) was collected.

RESULTS

Seventy-five (75) patients were recorded with newly-diagnosed T2DM pre-pandemic and fifty-four (54) patients were recorded with newly-diagnosed T2DM post-pandemic. There was no significant increase in T2DM cases and diabetic ketoacidosis (DKA) during pandemic and T2DM cases fell to below pre-pandemic levels in the 3rd and 4th year postpandemic. HbA1c and serum glucose were lower post-pandemic than pre-pandemic: 10.1% vs 11.9%, p = 0.008 and 12.0 mmol/L vs 16.1 mmol/L, p = 0.038 respectively.

CONCLUSION

The incidence of T2DM and DKA did not increase during the pandemic and further declined in year 3 and 4 post-pandemic. Lower HbA1c and serum glucose in the post-pandemic group may suggest improved screening services and greater access to medical care.

Human ; Covid-19 ; Diabetic Ketoacidosis ; Diabetes Mellitus, Type 2 ; Obesity